Literature DB >> 15754326

Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.

Valérie Gouyer1, Massimo Conti, Patrick Devos, Farid Zerimech, Marie-Christine Copin, Evelyne Créme, Alain Wurtz, Henri Porte, Guillemette Huet.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) play a role in the processes of extracellular matrix degradation. Changes in their expression levels have been observed in various tumor types, including lung carcinoma. However, their clinical significance and their prognostic importance in the progression of nonsmall cell lung carcinoma (NSCLC) remain to be specified. In this study, mRNA expression levels of MMP-1, MMP-9, TIMP-1, and TIMP-2 were evaluated in patients with resected NSCLC, and their associations with disease progression and prognosis were determined.
METHODS: Between June 1996 and December 1999, 116 patients underwent resection for NSCLC. Expression levels of MMPs and TIMPs were evaluated using Northern blot analysis in these NSCLC tissue samples and in 39 matched samples of normal lung tissue.
RESULTS: MMP-1, MMP-9, and TIMP-1 expression levels were increased in tumor samples compared with matched, corresponding normal tissues. In contrast, TIMP-2 expression was decreased in tumor samples. MMP-1 tumor expression was correlated significantly with the evolution of lymph node status and tumor-lymph node-metastasis (TNM) stage. In contrast, MMP-9 tumor expression was correlated significantly with increased T stage. TIMP-1 overexpression was an independent predictor of worse survival in patients with NSCLC that was not associated with other prognosis factors, such as TNM stage.
CONCLUSIONS: The overexpression of TIMP-1 was an independent prognostic marker in patients with NSCLC, and evaluating TIMP-1 may be important for identifying patients who are at greater risk of disease recurrence. (c) 2005 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15754326     DOI: 10.1002/cncr.20965

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

Review 1.  Cytokine functions of TIMP-1.

Authors:  Christian Ries
Journal:  Cell Mol Life Sci       Date:  2013-08-28       Impact factor: 9.261

2.  Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes.

Authors:  H Cui; B Seubert; E Stahl; H Dietz; U Reuning; L Moreno-Leon; M Ilie; P Hofman; H Nagase; B Mari; A Krüger
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

3.  Cannabidiol inhibits angiogenesis by multiple mechanisms.

Authors:  M Solinas; P Massi; A R Cantelmo; M G Cattaneo; R Cammarota; D Bartolini; V Cinquina; M Valenti; L M Vicentini; D M Noonan; A Albini; D Parolaro
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

4.  Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.

Authors:  Chin-Shiu Huang; Shih-Chieh Lyu; Miao-Lin Hu
Journal:  Invest New Drugs       Date:  2011-08-09       Impact factor: 3.850

5.  A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion.

Authors:  Pavan Adiseshaiah; Michelle Vaz; Narsa Machireddy; Dhananjaya V Kalvakolanu; Sekhar P Reddy
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

6.  Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.

Authors:  Karina Dahl Steffensen; Marianne Waldstrøm; Rikke Kølby Christensen; Annette Bartels; Nils Brünner; Anders Jakobsen
Journal:  BMC Cancer       Date:  2010-05-07       Impact factor: 4.430

7.  TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.

Authors:  Sven Mahner; Linn Woelber; Christine Eulenburg; Joerg Schwarz; Walter Carney; Fritz Jaenicke; Karin Milde-Langosch; Volkmar Mueller
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

8.  Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study.

Authors:  D Pastuszak-Lewandoska; J Kordiak; K H Czarnecka; M Migdalska-Sęk; E Nawrot; D Domańska-Senderowska; J M Kiszałkiewicz; A Antczak; P Górski; E Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-07-22       Impact factor: 3.064

Review 9.  Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets.

Authors:  Elin Hadler-Olsen; Jan-Olof Winberg; Lars Uhlin-Hansen
Journal:  Tumour Biol       Date:  2013-05-17

10.  Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF).

Authors:  Kathy Boon; Nathaniel W Bailey; Jun Yang; Mark P Steel; Steve Groshong; Dolly Kervitsky; Kevin K Brown; Marvin I Schwarz; David A Schwartz
Journal:  PLoS One       Date:  2009-04-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.